Forte Biosciences, Inc.
Price Action
Technical Summary
CONSOLIDATINGForte Biosciences, Inc. is in a consolidation phase, trading with mixed signals as moving averages converge. Relative strength is leading (RS Rating: 84), indicating clear outperformance against the broad market. Earnings growth of 78% provides fundamental context to the price action. Investors should exercise caution due to high volatility (113% annualized), which requires wider risk management.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $29.08 | -17.41% | BELOW |
| 50 SMA | $28.15 | -14.68% | BELOW |
| 100 SMA | $28.55 | -15.88% | BELOW |
| 150 SMA | $24.20 | -0.75% | BELOW |
| 200 SMA | $21.08 | +13.96% | ABOVE |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is FBRX in an uptrend right now?
FBRX has a trend score of 2/4 based on Minervini's Stage Analysis. Currently showing partial alignment - 2 of 4 trend criteria are met.
Is FBRX overbought or oversold?
FBRX's RSI (14) is 43. The stock is in neutral territory, neither overbought nor oversold.
Is FBRX outperforming the market?
FBRX has a Relative Strength (RS) Rating of 84 out of 99. Yes, FBRX is a market leader, outperforming 84% of all stocks over the past 12 months.
Where is FBRX in its 52-week range?
FBRX is trading at $24.02, which is 67% of its 52-week high ($35.80) and 60% above its 52-week low ($6.19).
How volatile is FBRX?
FBRX has a Beta of 1.47 and 52-week volatility of 113%. It's more volatile than the S&P 500 - expect bigger swings.